Best HIV treatment in Delhi NCRBest HIV Treatment in Delhi NCR: A Comprehensive GuideBest HIV treatment in Delhi NCR
Human Immunodeficiency Virus (HIV) attacks the immune system, making the body vulnerable to infections and diseases. Without treatment, HIV can progress to Acquired Immunodeficiency Syndrome (AIDS), which severely weakens the immune system.
However, advancements in medical science have made HIV a manageable condition. With timely diagnosis and proper treatment, individuals with HIV can lead long, healthy lives.
Managing HIV requires a comprehensive approach that includes: Accurate Diagnosis: Early detection is critical for effective management.
Antiretroviral Therapy (ART): The cornerstone of HIV treatment, ART helps suppress the virus and prevent its progression.
Counseling and Support: Emotional and mental well-being are equally important.
Regular Monitoring: Routine check-ups ensure the treatment plan remains effective.
Specialized clinics like Dr. Monga Clinic offer tailored solutions that address each patient's unique needs.
Dr. Monga Clinic is renowned for its expertise in managing HIV and related conditions. Here's why it is trusted by many: Experienced Specialists:The clinic is led by seasoned healthcare professionals with years of experience in treating HIV. Their in-depth knowledge ensures patients receive the most effective care. Comprehensive Approach:The treatment approach at Dr. Monga Clinic goes beyond just medication. It includes counseling, lifestyle modifications, and regular health check-ups to ensure overall well-being. Privacy and Confidentiality:Dr. Monga Clinic understands the sensitivity of HIV treatment and prioritizes patient confidentiality, creating a safe and supportive environment. State-of-the-Art Facilities:The clinic is equipped with advanced diagnostic and treatment facilities, ensuring that patients receive the best care under one roof. Convenient Location:
Situated in Delhi NCR, the clinic is easily accessible for residents of the region, making it a go-to choice for those seeking the Best HIV treatment in Delhi NCR.
Contact Information:
If you or someone you know needs expert care, call Dr. Monga Clinic at 8010977000 to book an appointment.
Starting HIV treatment at the earliest offers several advantages: Improved Quality of Life : With effective treatment, individuals can maintain a healthy lifestyle.
: With effective treatment, individuals can maintain a healthy lifestyle. Prevention of Complications : Early intervention reduces the risk of opportunistic infections.
: Early intervention reduces the risk of opportunistic infections. Undetectable Viral Load : ART can suppress the virus to undetectable levels, reducing the risk of transmission.
: ART can suppress the virus to undetectable levels, reducing the risk of transmission. Longevity : Proper treatment ensures a near-normal lifespan for people living with HIV.
: Proper treatment ensures a near-normal lifespan for people living with HIV.
There are several misconceptions surrounding HIV treatment. Let's debunk some of them: 'HIV is a death sentence.'
Fact: With modern treatment options, HIV is a manageable condition.
'ART cures HIV.'
Fact: While ART doesn't cure HIV, it effectively controls the virus, allowing individuals to live normal lives.
'HIV treatment is unaffordable.'
Fact: Clinics like Dr. Monga Clinic offer affordable and accessible treatment plans.
'People on ART can't have children.'
Fact: With proper medical guidance, individuals with HIV can have healthy children.
If you're seeking expert care, follow these steps: Consult a Specialist: Schedule an appointment with a trusted clinic like Dr. Monga Clinic.
Undergo Diagnostic Tests: Comprehensive testing ensures accurate diagnosis and treatment planning.
Follow Your Treatment Plan: Adhere to the prescribed medications and lifestyle changes.
Stay Informed: Educate yourself about the condition to make informed decisions.
Join Support Groups: Sharing experiences with others can provide emotional strength and motivation.
With a patient-centric approach, Dr. Monga Clinic has emerged as a beacon of hope for many. Their commitment to quality care, ethical practices, and continuous innovation makes them a preferred choice for HIV treatment in Delhi NCR. Contact Information:
If you or someone you know needs help, reach out to Dr. Monga Clinic today.
Phone: 8010977000
Location:20, National Park (Basement), Lajpat Nagar Part-4, New Delhi, Delhi 110024
Choosing the best HIV treatment in Delhi NCR is crucial for managing the condition effectively. With clinics like Dr. Monga Clinic, you can be assured of top-notch care, compassion, and support every step of the way. Take charge of your health and start your journey toward a fulfilling life today.
Living with HIV requires expert care and access to effective treatment options. In Delhi NCR, the availability of world-class medical facilities ensures that patients receive the best care possible. Among these, Dr. Monga Clinic stands out for its holistic approach, advanced treatment methods, and compassionate care. Whether you're seeking guidance, medications, or ongoing management, finding the best HIV treatment in Delhi NCR is now more accessible than ever.
Human Immunodeficiency Virus (HIV) attacks the immune system, making the body vulnerable to infections and diseases. Without treatment, HIV can progress to Acquired Immunodeficiency Syndrome (AIDS), which severely weakens the immune system.
However, advancements in medical science have made HIV a manageable condition. With timely diagnosis and proper treatment, individuals with HIV can lead long, healthy lives.
Managing HIV requires a comprehensive approach that includes: Accurate Diagnosis: Early detection is critical for effective management.
Antiretroviral Therapy (ART): The cornerstone of HIV treatment, ART helps suppress the virus and prevent its progression.
Counseling and Support: Emotional and mental well-being are equally important.
Regular Monitoring: Routine check-ups ensure the treatment plan remains effective.
Specialized clinics like Dr. Monga Clinic offer tailored solutions that address each patient's unique needs.
Dr. Monga Clinic is renowned for its expertise in managing HIV and related conditions. Here's why it is trusted by many: Experienced Specialists:The clinic is led by seasoned healthcare professionals with years of experience in treating HIV. Their in-depth knowledge ensures patients receive the most effective care. Comprehensive Approach:The treatment approach at Dr. Monga Clinic goes beyond just medication. It includes counseling, lifestyle modifications, and regular health check-ups to ensure overall well-being. Privacy and Confidentiality:Dr. Monga Clinic understands the sensitivity of HIV treatment and prioritizes patient confidentiality, creating a safe and supportive environment. State-of-the-Art Facilities:The clinic is equipped with advanced diagnostic and treatment facilities, ensuring that patients receive the best care under one roof. Convenient Location:
Situated in Delhi NCR, the clinic is easily accessible for residents of the region, making it a go-to choice for those seeking the Best HIV treatment in Delhi NCR.
Contact Information:
If you or someone you know needs expert care, call Dr. Monga Clinic at 8010977000 to book an appointment.
Starting HIV treatment at the earliest offers several advantages: Improved Quality of Life : With effective treatment, individuals can maintain a healthy lifestyle.
: With effective treatment, individuals can maintain a healthy lifestyle. Prevention of Complications : Early intervention reduces the risk of opportunistic infections.
: Early intervention reduces the risk of opportunistic infections. Undetectable Viral Load : ART can suppress the virus to undetectable levels, reducing the risk of transmission.
: ART can suppress the virus to undetectable levels, reducing the risk of transmission. Longevity: Proper treatment ensures a near-normal lifespan for people living with HIV.
There are several misconceptions surrounding HIV treatment. Let's debunk some of them: 'HIV is a death sentence.'
Fact: With modern treatment options, HIV is a manageable condition.
'ART cures HIV.'
Fact: While ART doesn't cure HIV, it effectively controls the virus, allowing individuals to live normal lives.
'HIV treatment is unaffordable.'
Fact: Clinics like Dr. Monga Clinic offer affordable and accessible treatment plans.
'People on ART can't have children.'
Fact: With proper medical guidance, individuals with HIV can have healthy children.
If you're seeking expert care, follow these steps: Consult a Specialist: Schedule an appointment with a trusted clinic like Dr. Monga Clinic.
Undergo Diagnostic Tests: Comprehensive testing ensures accurate diagnosis and treatment planning.
Follow Your Treatment Plan: Adhere to the prescribed medications and lifestyle changes.
Stay Informed: Educate yourself about the condition to make informed decisions.
Join Support Groups: Sharing experiences with others can provide emotional strength and motivation.
With a patient-centric approach, Dr. Monga Clinic has emerged as a beacon of hope for many. Their commitment to quality care, ethical practices, and continuous innovation makes them a preferred choice for HIV treatment in Delhi NCR. Contact Information:
If you or someone you know needs help, reach out to Dr. Monga Clinic today.
Phone: 8010977000
Location:20, National Park (Basement), Lajpat Nagar Part-4, New Delhi, Delhi 110024
Choosing the best HIV treatment in Delhi NCR is crucial for managing the condition effectively. With clinics like Dr. Monga Clinic, you can be assured of top-notch care, compassion, and support every step of the way. Take charge of your health and start your journey toward a fulfilling life today.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of the Canadian HIV-specialist biopharma. Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future milestones. Shares in Theratechnologies increased 25% at market open following the takeover announcement. The drugmaker has a market cap of $144.6m. The transaction, which will bring the currently Nasdaq-listed Theratechnologies back under private ownership, means Future Pak is paying a cash premium of 126% on the last closing share price for the biopharma. Theratechnologies has two products in the HIV arena that are approved by the US Food and Drug Administration (FDA), namely Egrifta (tesamorelin F8) and Trogarzo (ibalizumab-uiyk). Egrifta is approved to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy while Trogarzo is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistance. Egrifta WR took over from Egrifta SV in March 2025, offering a more convenient formulation. Expected to close in Q4, the deal will close a sale process that has fluctuated over the past year. Future Pak's first attempt to acquire Theratechnologies was rebuffed in August 2024, with the biopharma deeming the $100m offer too low. Future Pak returned to the deal table in January 2025. Theratechnologies had already entered an exclusivity agreement with another potential acquirer, meaning Future Pak was once again turned away. Theratechnologies eventually opened the sale process to other parties, opening the door for a potential deal with the contract manufacturer. In April 2025, Future Pak tabled a $255 offer, which has now been accepted by the drugmaker. Theratechnologies reported 2024 revenue of $85.9m, a 5% increase from the $81.8m accumulated in 2023. Whilst the company reported a positive EBITDA for the year, it struggled with supply for Egrifta WR due to an issue with a contract manufacturer. Still, sales of the drug grew 12%, unlike Trogarzo, which dropped 8% due to 'competitive pressures' in the multidrug-resistant segment of the HIV market. 'This transaction is the result of a thorough and deliberate sale process aimed at maximising value for our shareholders,' stated Frank Holler, Theratechnologies' chair of the board of directors. 'Future Pak's interest in acquiring Theratechnologies represents a vote of confidence in the company we've built, recognising our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.' Last year, Future Pak also made multiple unsuccessful attempts to acquire Vanda Pharmaceuticals, the developer of sleep disorder drug Hetlioz. Cycle Therapeutics ultimately won out, acquiring in a $466m deal. "Theratechnologies shares surge 25% amid $254m Future Pak takeover" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
17 hours ago
- Business Insider
10 African countries most exposed to Trump's health aid cuts
Several African countries' health systems remain critically vulnerable to the fallout from President Donald Trump's ongoing efforts to scale back U.S. foreign assistance, most notably through the dismantling of the U.S. Agency for International Development (USAID). Several African countries are critically vulnerable due to reduced U.S. foreign assistance, particularly from cuts to USAID programs. For some nations like Somalia and South Sudan, U.S. health aid constitutes over 200% of their government health spending, making them heavily reliant. Cuts to U.S. health aid threaten African public health progress and may lead to global health risks due to weakened disease surveillance capabilities. Newly released data shows how heavily African health systems rely on U.S. aid, raising serious concerns about the impact of abrupt funding cuts on public health across the continent. According to the Center for Global Development, the United States has been a central player in supporting global health supply chains, particularly through the Global Health Supply Chain – Procurement and Supply Management (GHSC-PSM) project. In 2024 alone, the project supported 73 countries and disbursed $1.15 billion in donated health commodities and technical assistance. The majority of the funding focused on HIV (71.1%), followed by malaria (20.3%), family planning (7%), and maternal, neonatal, and child health (1.5%). In nine countries, this aid accounted for more than 10% of total government health spending, levels that are difficult to replace with domestic resources. Trump's freeze on $72 billion in U.S. foreign aid spending led to the suspension of hundreds of development projects in over 200 countries and territories, affecting nearly 10,000 USAID personnel. In total, the administration terminated 5,341 projects worth $75 billion and initiated a sharp reduction in USAID staffing, signaling a dramatic shift in America's approach to global development. For Africa, where U.S. aid often supports core health services, these actions threaten to reverse years of progress in disease control, maternal health, and emergency preparedness, while exposing millions to increased health risks. African nations most hit by US health aid cuts Recent data sourced from Business Daily Africa shows that countries like Somalia, South Sudan, and Malawi are among the most at risk, with U.S. health aid making up 237%, 235%, and 207% of their government health spending, respectively. The chart below ranks the top 10 African countries most vulnerable to Trump's health aid cuts, based on U.S. health aid as a percentage of government health spending: In over 20 African countries, U.S. assistance forms a vital share of national health budgets. For nations like Uganda, Liberia, and Mozambique, it covers more than 80% of health spending, supporting key services such as HIV/AIDS treatment, immunizations, and maternal care. The impact would be especially severe in fragile states like Somalia and South Sudan, where local systems cannot absorb such a shock. In these countries, U.S. aid underpins essential services, and its loss could trigger a collapse in healthcare delivery and a rise in preventable diseases.
Scientific American
18 hours ago
- Scientific American
U.S. Budget Cuts Are Robbing Early-Career Scientists of Their Future
As a young doctoral researcher at a university in the southern U.S., Camilo felt like he was finally closing in on his dream of becoming a leader in the next generation of HIV scholars. His recent work has helped hundreds of LGBTQ+ Latino people access HIV prevention programs and preexposure prophylaxis, or PrEP, a medication that reduces HIV infection risk. But these lifesaving efforts—and Camilo's hopes of a career focused on directly helping people in his community—came to a screeching halt one recent Friday afternoon: he opened an e-mail that said a National Institutes of Health grant, vital to his work, had been terminated. 'I saw an image of a floating pair of scissors clipping my future,' says Camilo, who asked to use a pseudonym, citing fear of retaliation. Since researchers first began receiving grant termination letters in late February, massive chunks of federal funding for science and health have been canceled on a near-weekly basis. The Trump administration has framed these cuts as a way to reduce wasteful spending, refocus research priorities and eliminate ideological bias. Grants have been flagged for containing keywords such as 'women,' 'diverse,' 'minority' and 'racially.' Camilo's research checked all the boxes for the administration's crackdown on so-called diversity, equity and inclusion (DEI) research. He had been expecting the bad news, but when it came, it was still crushing. 'You're losing everything,' he says. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Grant Watch, a project tracking Trump's scientific funding cancellations, has tallied more than 2,482 terminated NIH grants worth $8.7 billion and 1,669 terminated National Science Foundation grants worth $1.5 billion as of mid-June. An NSF spokesperson declined an interview request from Scientific American but wrote in an e-mail that 'we remain committed to awarding grants and funding all areas of science and engineering.' The Department of Health and Human Services did not respond to direct requests for an interview for this article. An NIH representative did not respond to a list of written questions but said the agency 'is taking action to terminate research funding that is not aligned with NIH and HHS priorities.' 'I saw an image of a floating pair of scissors clipping my future.' —Camilo, doctoral researcher On June 16 Judge William Young of the U.S. District Court for the District of Massachusetts ruled against cuts to hundreds of grants for projects through the NIH, calling these cuts 'void and illegal' and indicating that funding must be reinstated. Experts expect the Trump administration will appeal the ruling, which does not apply to all of the terminated grants compiled by Grant Watch. Virtually every research sector has been disrupted in some way since Trump took office and issued a slew of executive orders affecting science and health care. Tens of thousands of federal employees at the HHS, NIH and other science- and health-related agencies have been laid off. Universities are bracing for major federal funding cuts by freezing new hiring and cutting graduate student positions. Private research companies and industries have also seen some federal support severed—including support for the development of new vaccines and cancer treatments. 'When you cut fellowships and grants, you're cutting the people that are doing the work.' —Andrew Pekosz, virologist, Johns Hopkins University Of the many thousands of researchers grappling with the fallout, one group is being disproportionately affected: early-career scientists. Senior researchers often have a diversity of funding streams, but for those starting out in the field, 'grants serve as the foundation for an entire career of work,' says Megan Ranney, dean of the Yale School of Public Health. With the cuts, 'there are some [early-career researchers] who we will undoubtedly lose from the scientific and health enterprises.' Scientific American posted on a Reddit space for scientists, researchers and lab workers to ask people how they are grappling with the professional and personal whiplash of these interruptions. More than 50 people responded with public comments; dozens more sent private messages expressing fears, frustrations and concerns. We interviewed several of them—and other junior researchers—about how the cuts are affecting their current and future work and what the long-term consequences may be for the U.S. Research Interrupted Students and postdoctoral researchers perform the vast majority of research at academic institutions, so in addition to disrupting individual lives, the cuts have thrown whole laboratories into disarray. 'When you cut fellowships and grants, you're cutting the people that are doing the work,' says Andrew Pekosz, a virologist who leads a lab at the Johns Hopkins Bloomberg School of Public Health. Pekosz's lab had recently lost a COVID-related grant that was supposed to run until September. which forced him to dismiss a postdoc and a research associate because he lacked funding for their salaries. He was able to cobble together support for a Ph.D. student on the project but had to shorten the timeline for the research. Although the lab's grant is among those that Judge Young ordered the NIH to restore, much damage has already been done. 'There's just an overwhelming sense of insecurity.' —Sierra Wilson, Ph.D. student, University of Pittsburgh Labs that still have funding are also working under high pressure and low morale. 'We're constantly asking our PI [principal investigator], 'Is everything going to be okay? Are we going to be safe?'' says R.K., an undergraduate student at a lab in the Midwest that's investigating treatments for a genetic disease. (R.K. asked to be identified by his initials, citing fear that speaking out could harm his future career.) At weekly meetings, he says, the lab's principal investigator has been pushing the team to publish more papers 'in order to show our progress to donor organizations.' If the researchers' NIH funding shrinks, he says, 'we would need to persuade our other donors for more money to make up the gap.' Applied across thousands of U.S. labs, these losses—both tangible and psychological—will add up, Pekosz says. 'We're going to see a massive downsizing of biomedical research efforts because there simply is not going to be the funding available to maintain the current level,' he says. Recent data suggest this is likely to prove correct. For example, according to a 2023 JAMA Health Forum paper, of the 356 drugs that gained Food and Drug Administration approval between 2010 and 2019, more than 84 percent received research funding from the NIH before approval. This research was powered by early-career workers: billions of dollars in NIH funding supported graduate students, postdocs and research staff who conducted the work. Under the current budget cuts, however, 'all of this is at risk,' says Fred Ledley, a co-author of the 2023 paper and a professor of natural and applied sciences at Bentley University. Deeply Personal The termination letter for Calimo's grant, which is not affected by Judge Young's ruling, said that it 'no longer [effectuated] agency priorities' and that 'research programs based primarily on artificial and non-scientific categories, including amorphous equity objectives, are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life or reduce illness.' Not only did these claims completely contradict the original score that NIH grant reviewers gave Camilo's application, reading the letter made him feel like he was being 'attacked,' he says. Early-career grants are both crucial stepping stones to larger grants and recognition of a rising researcher's potential. The way the Trump administration's termination letters are worded 'delegitimates the scientists and the work they do,' Ranney says. 'There's often a deeply personal aspect.' 'I just feel very let down and betrayed by my country.' —Alex, postdoc, University of Colorado Sometimes, that personal aspect is literally about the researchers themselves. Sierra Wilson, a Ph.D. student at the University of Pittsburgh, assumed her liver-regeneration research would be safe from the cuts. But because Wilson is a first-generation college student from a low-income household, her funding came from a program that aimed to increase diversity in biomedical research, and according to the NIH spokesperson, that program is now 'expired.' When Wilson read her termination letter in late April, she suspected it must be related not to her research but to her classification as an underrepresented scholar. In her case, she says, the federal cuts appear to be targeting 'people themselves—which feels more discriminatory.' The NIH spokesperson did not respond to Scientific American's question about the allegation that the termination of grants in the now expired program appeared to be based on researchers' identity or background. According to the spokesperson, 'Grantees may appeal terminations for nonalignment with agency priorities.' Wilson sent an appeal request in May, but she does not expect a timely resolution, and to her knowledge, her grant is not affected by Judge Young's decision. University personnel who helped her with the appeals process told her that they expect she will have graduated by the time the NIH gets back to her. A number of junior researchers say all these blows are taking a heavy toll on their mental health. One of them is Alex, a postdoc at the University of Colorado, whose last name has been withheld for privacy at her request. Alex, who says she comes from a low socioeconomic background and served in the military before pursuing research developing flu vaccines, reports recurring nightmares about losing her postdoctoral job. She 'spirals' each time she sees bad news about science at stake, she says, and has recently developed blood pressure issues. 'I just feel very let down and betrayed by my country,' she says. 'I feel ashamed I even served it.' The Lost Generation of Scientists Scientists who are just entering their field can spark fresh ideas and bring an appetite for change. But dwindling funding and opportunities threaten to 'choke off' this influx of new talent—further constraining the already competitive job market—Pekosz says. He has even seen signs of the scientist-hiring drought spilling over into industry. His graduating Ph.D. students are struggling to secure jobs, he says, adding that his inbox is full of e-mails from prospective students as well as laid-off federal scientists seeking positions in his lab. Wilson has fading hopes for securing a job in academia when she graduates this fall. 'With all these grant and job terminations, the market is flooded, and people aren't hiring because [they don't know] how things will work out,' Wilson says. 'There's just an overwhelming sense of insecurity.' Many scientists, including early-career ones, are contemplating leaving the U.S. to find better support for their research. R.K., who plans to pursue a dual medical degree and Ph.D., is now considering applying to programs in Asia and Europe. Alex, likewise, is strongly thinking about leaving the country. 'I would love to be a PI,' she says. 'But there's no hope left here.' If available scientific talent continues to decline in the U.S., experts anticipate a potential domino effect on the economy. In 2024 every dollar invested in NIH research generated a $2.56 return, so the U.S. economy will likely feel the aftershocks of the recent cuts relatively quickly, Ranney says. In the longer term, scientific discoveries 'will start to stagnate,' she says. 'We need to recognize that we have a tremendous amount of power.' —Tyler Yasaka, medical and Ph.D. student, University of Pittsburgh There's also a likelihood that science fields will become a less appealing choice for incoming college students. 'I worry that we're going to see a loss of basic scientific skill and knowledge as fewer people go into science,' Ranney says. If the pipeline of new talent slows, the nation's position as a global leader in science will be difficult to maintain—or to recover once it's gone, she says. It's going to be impossible to replace all the lost federal funding, Ranney says. The remaining hope, then, is that 'we can reverse course,' she says. Some scientists are uniting and pushing back. Tyler Yasaka, a dual medical and Ph.D. student at the University of Pittsburgh, is part of an informal committee at the University of Pittsburgh Medical Center's Hillman Cancer Center that's brainstorming actions researchers and students can take, such as advocating for science in front of elected officials at Capitol Hill. He is also independently launching a podcast to share scientists' experiences with funding. 'I think most scientists aren't comfortable speaking out publicly, but if we value democracy, we have an obligation to use our voices,' Yasaka says. 'We need to recognize that we have a tremendous amount of power.' Fortunately for Camilo, his university has found institutional funds to support the remainder of his Ph.D. But he no longer sees a clear path forward after graduation to continue his research on HIV and LGBTQ+ health among Latinos in the U.S.—public health issues that are personally important to him. 'It's sad and upsetting,' he says. 'I do not want to give up on my community.'
